Israel Englander Janux Therapeutics, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.93 - $49.75 $523,950 - $3.29 Million	-66,072 Reduced 91.95%	5,784 $217,000
Q4 2023 Feb 14, 2024	SELL	$5.85 - $11.7 $388,381 - $776,763	-66,390 Reduced 48.02%	71,856 $771,000
Q2 2023 Aug 14, 2023	BUY	$11.08 - $15.92 $1.15 Million - $1.66 Million	104,143 Added 305.38%	138,246 $1.64 Million
Q1 2023 May 15, 2023	SELL	$11.25 - $22.21 $65,328 - $128,973	-5,807 Reduced 14.55%	34,103 $413,000
Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $443,001 - $728,756	39,910 New	39,910 $526,000

166

37.6M

85.3K

654K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.